Efficacy, Safety of an Investigational Dose of Semaglutide Injection in Adults With Type 2 Diabetes

Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, discusses the findings around the efficacy and safety of the 2 mg dose of semaglutide for the treatment of type 2 diabetes.

Pharmacy Times interviewed Michael Radin, MD, executive director, Diabetes Cardio Renal Medical Director Team, Medical Affairs, Novo Nordisk, on results from the SUSTAIN FORTE phase 3 clinical trial evaluating an investigational 2 mg dose of semaglutide (Ozempic; Novo Nordisk) injection in adults with type 2 diabetes.

During the discussion, Radin addresses the findings around the efficacy and safety of the 2 mg dose of semaglutide among this patient population.

Related Content:

ADARetailDiabetesConference
Pharmacist Moms: Coffee With Suzy - Episode 19
GSK Releases Positive Phase 3 Data for Its Respiratory Syncytial Virus Vaccine
USP Expert: It’s Critical Pharmacists Have Conversations With Patients on Adherence, Storage Issues That Result in Antimicrobial Resistance